Trialing of ISS in Patients With CRPS
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03954080 |
Recruitment Status :
Completed
First Posted : May 17, 2019
Last Update Posted : April 5, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
CRPS I Causalgia | Device: Intraspinal-optimal stim therapy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 16 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Trialing of Intra-spinal Stimulation in Patients With Complex Regional Pain Syndrome or Causalgia |
Actual Study Start Date : | June 13, 2019 |
Actual Primary Completion Date : | March 23, 2022 |
Actual Study Completion Date : | March 31, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: ISS |
Device: Intraspinal-optimal stim therapy
During the trial, percutaneous lead(s) will be implanted, following standard clinical practices, in the posterior epidural space with the final lead position located in the optimal area to provide pain relief by stimulating neural tissue in order to create paresthesia(s) only on the painful dermatome(s). During Intraspinal-Optimal Stim, a set of electrodes in the stimulation lead(s) will deliver a charge-balanced, pulsed electrical signal with stimulation parameters (frequency, pulse width, and amplitude) within the FDA approved specifications of the commercially available external neurostimulator. These will be adjusted to produce paresthesia coverage of the painful area. Patients that will report equal or greater than 50% reduction in pain, relative to baseline pain, may undergo permanent implantation of a commercially available neurostimulator (INS). This will require a surgical intervention to implant stimulation leads, INS and anchoring hardware followed by therapy programming. |
- Change in pain relative to baseline pain (i.e. prior to therapy) at 3 months after device activation for providing Intraspinal-Optimal Stim therapy [ Time Frame: 3 months after therapy activation ]Change in pain relative to baseline pain (i.e. prior to therapy) at 3 months after device activation for providing Intraspinal-Optimal Stim therapy. Pain scoring will be based on the 11-points (0 to 10) numerical pain rating scale. In this scale a value of 0 means no pain, and a value of 10 reflects the worst imaginable pain.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Capable of giving written informed consent to participate in this clinical study.
- Must be 18 years old or older.
- Predominant pain in one or both of the lower limbs attributed to CRPS or causalgia that has been refractory to conservative therapy for at least 3 months.
- Average pain intensity larger or equal to 6 on the numeric pain rating scale (NPRS).
- Appropriate candidate for spinal cord stimulation as determined by the Investigator.
- Subjects must be on a stable dose of pain medication regimen for at least 1 month.
- Must be able to comply with the requirements of study visits.
- Have cognitive ability of operate the remote control and follow therapy instructions and directions by clinicians.
Exclusion Criteria:
- Systemic infection.
- Any other active implanted device.
- Evidence of serious neurological, psychological or psychiatric disorders.
- Previous posterior decompressive laminectomy that precludes appropriate posterior epidural placement of stimulation lead(s).
- Patient who are pregnant, breast-feeding or women of childbearing potential with positive pregnancy tests.
- Human immunodeficiency virus (HIV) infection or a clinically significant infection.
- A clinically significant disorder such as cerebrovascular disease, pulmonary infarction, ischemic heart disease, cardiac dysrhythmia, myocardial infarction, or congestive heart failure or any other as determined by the investigator.
- Uncontrolled diabetes, uncontrolled pulmonary disease, or uncontrolled hypertension.
- Patients who have evidence of major psychiatric disease, mental disorder, drug dependency, alcohol dependency, or substance abuse disorders.
- Patients who have progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, acute herniated disc, or any other as determined by investigator.
- Medical condition or pain in other body areas determined by the Investigator as interfering with study procedures, accurate pain reporting, and/or confound evaluation of study end points.
- Concurrent participation in another clinical study.
- Involvement in an injury or disability claim under current litigation or a pending or approved workers' compensation claim.
- Escalating or changing pain condition over the last 30 days that creates difficulty of pain evaluation by the patient.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03954080
United States, Illinois | |
Millennium Pain Center | |
Bloomington, Illinois, United States, 61704 |
Principal Investigator: | Ricardo Vallejo, MD,PhD | Millennium Pain Center |
Responsible Party: | Millennium Pain Center |
ClinicalTrials.gov Identifier: | NCT03954080 |
Other Study ID Numbers: |
MPC-2019ISS/CRPS |
First Posted: | May 17, 2019 Key Record Dates |
Last Update Posted: | April 5, 2022 |
Last Verified: | April 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Causalgia Complex Regional Pain Syndromes Autonomic Nervous System Diseases Nervous System Diseases |
Peripheral Nervous System Diseases Neuromuscular Diseases Neuralgia |